Therefore, the clinical treatment of KD with active anti-inflammatory, anticoagulant, high-dose gamma globulin infusion, etc., can also block the secretion of HMGB1 at an early stage to prevent coronary artery injury and reduce the occurrence of coronary aneurysms. The gene discussed is HMGB1; the disease is coronary aneurysm.